Disease perceptions among people with Crohn's disease

Inflammatory Bowel Diseases

Volumn 14, Issue 8, 2008, Pages 1097-1101

  Kane, Sunanda V ^a   Loftus Jr , Edward V ^a   Dubinsky, Marla C ^b   Sederman, Robert ^c  

^a MAYO CLINIC   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c CI Consulting   (United States)

Author keywords

Crohn's disease; Patient perceptions; Therapy

Indexed keywords

AZATHIOPRINE; BALSALAZIDE; CORTICOSTEROID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; OLSALAZINE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BIOLOGICAL THERAPY; CLINICAL DECISION MAKING; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; ONLINE SYSTEM; PATIENT ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; SELF REPORT; SEX RATIO; SYMPTOMATOLOGY; TELEPHONE; UNSPECIFIED SIDE EFFECT;

ADULT; CROHN DISEASE; DECISION MAKING; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; PERCEPTION; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 49749141464     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20418     Document Type: Article

References (10)

1. Hanauer SB, Sandborn W. Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2001;96:635-643.
2. Sorenson VZ, Olsen BG, Binder V. Life prospects and quality of life in patients with Crohn's disease. Gut. 1987;28:383-385.
3. Drossman DA, Leserman J, Li Z, et al. The rating form of IBD patient concerns: a new measure of health status. Psychosom Med. 1991;53: 701-712.
4. Irvine EJ, Feagan BG, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology. 1994;106:287-296.
5. Casati J, Toner BB, de Rooy EC, et al. Concerns of patients with inflammatory bowel disease: a review of emerging themes. Dig Dis Sci. 2000;45:26-31.
6. Graff LA, Walker JR, Lix L, et al. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol. 2006;4:1491-1501.
7. Sands B, Siegel C, Hass S, et al. Crohn's disease patients' willingness to accept the risks of serious adverse events in exchange for clinical benefits. Digestive Diseases Week, May 20-25, 2006. Los Angeles, CA. Abstract W1200.
8. Siegel CA, Levy C, Mackenzie TA, et al. Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Am J Gastroenterol. 2006;101(9 Suppl):S438.
9. Hommes D, Baert F, van Assche G, et al. Management of recent onset Crohn's disease: a controlled, randomized trial comparing step-up and top-down therapy. Gastroenterology. 2005;129:370.
10. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128:862-869.